Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 9/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.37 |
| ▸ | LMNA | P02545 | 5/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.35 |
| ▸ | USP2 | O75604 | 7/20 | 0.35 |
| ▸ | MEN1 | O00255 | 6/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 5/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5318166 | 1.00 | CLK4 (0.37) | CLK4CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL5914150 | 0.88 | CFD (0.35) | CLK4CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL5914240 | 0.86 | CLK4 (0.46) | CLK4CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL5914244 | 0.86 | CLK4 (0.46) | CLK4CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL5913994 | 0.83 | MAPK14 (0.42) | MAPK14 | |
| SCHEMBL5914018 | 0.83 | MAPK14 (0.42) | MAPK14 | |
| SCHEMBL5914289 | 0.82 | CARM1 (0.38) | MAPK14 | |
| SCHEMBL5914294 | 0.82 | CARM1 (0.38) | MAPK14 | |
| SCHEMBL5312839 | 0.81 | MAPK14 (0.35) | CYP3A4MAPK14USP2TSHRALOX15 | |
| SCHEMBL5914418 | 0.79 | MAPK14 (0.40) | CLK4CYP1A2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794135-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006037117-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | MAPT, MYLK2, IAPP | CLK4 2319/4885CYP1A2 1159/4885CYP3A4 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.